China’s authorities have approved Enhertu (trastuzumab deruxtecan) as the first HER2-directed antibody-drug conjugate for patients with HER2-positive metastatic gastric cancer.

• Clinical Basis: Approval is supported by the DESTINY-Gastric04 Phase 3 trial, demonstrating survival benefits in the second-line treatment setting.
• Technical Specification: The therapy uses DXd ADC technology, linking a HER2 monoclonal antibody to topoisomerase I inhibitor payloads.
• Market Significance: This is the sixth approval for Enhertu in China over the past three years.

This summary is based on a press release issued by Daiichi Sankyo Co., Ltd.